QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe
QIAGEN launched the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel in Europe, expanding its bloodstream infection testing menu. The new panel detects 13 gram-negative pathogen targets and 18 antimicrobial resistance markers in about one hour, complementing the existing gram-positive panel for comprehensive coverage. Regulatory review by the FDA is underway for the U.S.
Key figures
- Turnaround time
- about one hour
- Total amr markers
- 28
- Instruments placed
- 5200
- Total pathogen targets
- 33
- Gram negative pathogen targets
- 13
- Antimicrobial resistance markers gn
- 18
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.